Canifug

Clotrimazol

Method of action: Antifungal Broad Spectrum, Antiprotozoal, Gynecological Antiinfectives And Antiseptics, Ophthalmologicals, Trichomonocidal

Treatment option: Infection, Candidiasis,Vaginal, Empeines, Stomatitis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Canifug

What is Canifug? (Clotrimazol)

Property	Description
Active ingredient	Clotrimazol
Form	Topical Cream, Vaginal Suppositories (Cremolum), Solution
Pharmacological class	Antifungal Agent, Imidazole Derivative
General purpose	To combat fungal and yeast infections
Origin	Synthetic Organic Compound

Clotrimazol: The Active Ingredient and Pharmacological Classification

Canifug is a pharmaceutical monopreparation whose core therapeutic effect relies on the synthetic organic compound known by its active ingredient, Clotrimazol. This substance belongs to the pharmacological class of antifungal agents, specifically categorized as an imidazole derivative and referred to as an antimycotic. The established profile of Clotrimazol defines it as a broad-spectrum antimycotic effective against a wide range of fungi. This class of drug is recognized in pharmacology for its application in addressing superficial fungal infections.

Form and Composition: The Structure of the Canifug Product

The Canifug range encompasses various dosage forms engineered for local application, ensuring the Clotrimazol agent is delivered directly to the required site. Key presentations include the topical cream, the solution, and specialized vaginal suppositories, often referred to as Cremolum. The brand Canifug is generally positioned for over-the-counter (OTC) access in its topical and intravaginal forms, reflecting its established profile for targeted use. The formulations combine the single active ingredient with an inactive base/vehicle, such as a cream base or a lipophilic base, which dictates the physical properties and route of administration, whether topical or intravaginal.

How Canifug Generally Works to Combat Fungal Organisms

The primary function of the Clotrimazol in Canifug is to suppress or eliminate fungal organisms by selectively targeting their core structures. This action involves the inhibition of a key enzyme necessary for ergosterol biosynthesis, a vital component of the fungal cell membrane. This process results in the instability of the fungal cell. The agent's purpose is to exert a direct, concentrated antimycotic action, which halts the growth and reproductive capability of the fungi, thereby reducing the population responsible for the infection and offering therapeutic relief. This principle makes it suitable for addressing issues such as yeast overgrowth.

Regulatory References

What side effects are possible with Canifug?

The officially documented safety profile for Clotrimazol (Canifug) focuses predominantly on localized reactions, though the possibility of rare, systemic effects is noted in regulatory documents. Adverse reactions are grouped by System-Organ Class (SOC) for reporting purposes, primarily involving the Skin and Subcutaneous Tissue Disorders and the Immune System Disorders.

Documented Adverse Reactions

Adverse reactions are mostly observed at the application site and may include localized symptoms such as burning sensation, stinging, itching (pruritus), and erythema (redness). Other dermatological effects listed in regulatory sources include rash, blistering, peeling, and local edema. Many of these reactions are derived from post-marketing reports, meaning their exact frequency often cannot be estimated with reliable precision, though local irritation may be considered common.

Serious Adverse Reactions and Safety Constraints

Although minimal systemic absorption is expected, the regulatory profile includes reports of rare Systemic Hypersensitivity Reactions under the Immune System Disorders class. These serious reactions may manifest as anaphylaxis, accompanied by symptoms like syncope (fainting), hypotension, and dyspnea (breathing difficulty).

Population and Material Restrictions

Safety statements confirm that use during Pregnancy and Lactation requires medical consultation, despite the low risk attributed to minimal systemic exposure. A critical safety limitation noted in the official label is the potential for the product's excipients to damage latex contraceptive devices (such as condoms or diaphragms), which may compromise their effectiveness. The medicine is contraindicated in individuals with a known hypersensitivity to the active substance or its components.

Overdose and Emergency Response

The official regulatory documents state that the risk of acute intoxication is classified as unlikely for this medication. This classification is based on the minimal systemic absorption following its intended topical or vaginal application, meaning an overdose from simple dose excess is not expected to result in a life-threatening situation.

The primary focus of official overdose guidance is the management of accidental oral ingestion. Should this occur, officially documented clinical symptoms may include dizziness, nausea, and vomiting. Treatment is specified as being primarily symptomatic, and procedural steps, such as gastric lavage, should only be considered if clinical manifestations become apparent, and only under the strict constraint that the airway can be adequately protected. Regulatory labels confirm that no specific antidote is known.

Immediate medical attention is explicitly required for any suspected accidental ingestion. Furthermore, the highest level of emergency action is mandated for the rare occurrence of severe systemic reactions, such as anaphylaxis, syncope, hypotension, or dyspnea, which are considered life-threatening events that trigger urgent help according to official safety guidance. Finally, regulatory information requires close monitoring for signs of overdosage of certain co-administered immunosuppressants, specifically tacrolimus or sirolimus.

Therapeutic Uses of Canifug

Canifug is used for the management of symptoms associated with specific fungal infections in the vaginal area. The main applications involve the relief of symptoms related to infections of the vagina and the external genital area, such as vulvitis, which are often caused by yeast-like fungi. The medicine's indications are primarily focused on addressing key symptoms, including itching, burning, redness, and abnormal vaginal discharge.

The therapeutic goal is the symptomatic relief of these uncomfortable manifestations to help restore patient comfort. The medicine is intended solely for external and vaginal use to manage these localized symptoms.

Quick Fact: Relief for Vaginal and External Genital Discomfort

Regulatory References

EMA therapeutic product overview

Eligibility and Restrictions for Use

Eligibility for Canifug (Clotrimazole) as Defined by Regulators

The official eligibility profile for Canifug is defined by formal contraindications, age limits, and conditional use requirements, focusing strictly on population groups.

Eligibility Classification	Population Constraint (Official Status)
Absolute Contraindication	Individuals with known hypersensitivity or allergy to clotrimazole or any component of the formulation.
Pediatric Restriction	Vaginal products are restricted for use in children under 12 years without medical consultation. Topical products are restricted for children under 2 years without medical direction.
Conditional Use	Use requires consultation if the infection is a first-time vaginal occurrence, is frequently recurring (e.g., 3 in 6 months), or if the patient has underlying serious medical causes (e.g., diabetes or immunocompromised status).
Pregnancy/Lactation Status	Use in the first trimester of pregnancy is restricted and should only proceed if clearly indicated. Caution is advised during lactation, and topical application to the breast is advised against.

Connection to the Overall Eligibility Profile

Regulatory documentation establishes eligibility by defining absolute exclusions (hypersensitivity) and imposing mandatory consultation requirements for specific age groups and patient categories. These rules strictly delineate the boundaries between permitted over-the-counter use and situations requiring professional guidance due to elevated risk factors or limited data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail two primary categories of interaction constraints for Canifug (Clotrimazole), specifically concerning medical devices and systemic drug exposure.

Interactions with Non-Medicinal Products

Components of Canifug, when used vaginally, have been found to cause damage to the material of certain contraceptive products.

Product Category	Constraint	Requirement
Latex Contraceptives	Reduction in effectiveness (due to material damage)	Use alternative non-latex precautions for at least five days following use

Systemic Drug-Drug Interactions

Although systemic absorption of the active ingredient is minimal, the potential for drug-drug interactions exists with certain orally administered immunosuppressant medications. These interactions are related to the active ingredient's metabolism and can lead to elevated plasma concentrations of the co-administered drug.

Interacting Medicine	Interaction Result	Constraint/Requirement
Tacrolimus (oral)	Increased plasma levels	Close monitoring of Tacrolimus plasma levels is required
Sirolimus (oral)	Increased plasma levels	Close monitoring of Sirolimus plasma levels is required

These constraints ensure that patients are aware of the potential for reduced contraceptive efficacy and the need for therapeutic drug monitoring when co-administering specific immunosuppressants.

Mechanism of Action

Canifug functions as a selective, non-competitive inhibitor of the farnesyl pyrophosphate synthase (FPPS) enzyme within the mevalonate pathway of osteoclasts. Upon cellular uptake, the bisphosphonate structure is metabolized, releasing the active component. This component binds directly to the catalytic site of FPPS, effectively preventing the conversion of isopentenyl diphosphate and dimethylallyl diphosphate into farnesyl pyrophosphate. This inhibition blocks the subsequent prenylation of small GTPases, such as Rho and Rac, which are critical for cytoskeletal rearrangement and formation of the osteoclast ruffled border. The disruption of these signaling proteins impairs the ability of osteoclasts to adhere to the bone surface and execute their resorptive function. The resulting cellular dysfunction leads to a reduction in the rate of bone matrix degradation and mineral release, thereby modulating overall skeletal physiological turnover.

Dosage and Administration Information

Administration Instructions

The administration protocol for Canifug, which is a vaginal suppository formulation of clotrimazole, follows established guidelines. Adherence to these specific instructions ensures the standardized use of the medicine.

Dosing and Administration Route

The established dosage for adult women is one vaginal suppository to be administered daily. The suppository must be inserted into the vagina, preferably while the patient is lying on her back with the legs slightly bent, to facilitate proper placement.

Administration Detail	Instruction
Route	Vaginal
Dose	One suppository
Frequency/Duration	Once daily for three consecutive days
Target Age	Adult women

Procedural and Timing Rules

The treatment course is fixed at three consecutive days and should ideally be completed before the onset of menstruation. Treatment should preferably not be carried out during menstruation.

If a dose is missed, instructions indicate not to use a double dose to compensate. Instead, the patient should continue the treatment with the next single scheduled dose, resuming the original dosing pattern. The entire course must be completed as prescribed, even if symptoms improve.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Canifug

Evidence for Use in Acute Vaginal Yeast Infections (VVC)

Research examining the use of clotrimazol for acute vaginal yeast infections (VVC), which are conditions characterized by fluctuating or episodic manifestations, primarily involves Randomized Controlled Trials (RCTs). These are studies used in research exploring how symptoms change over time and focus on defined groups of patients. In these trials, the medicine was evaluated against either an inactive treatment (placebo) or other antifungal medicines.

Studies explored the treatment of symptomatic adult women with confirmed fungal infections. Researchers were focused on two main axes: mycological outcomes, which monitored the absence of the fungus itself; and clinical outcomes, which tracked patient-reported outcomes describing perceived discomfort, such as the resolution of itching, burning, and abnormal discharge. Trials reported data from comparisons with non-active controls, which helped contextualize how patients reported their experience over the short-term.

Most research exploring short-term symptom changes for VVC is older. Follow-up durations were limited across many studies. This means that research focusing on episodes where symptoms become more noticeable is plentiful, but long-term outcomes are not well characterized. For instance, data for certain groups, such as those with particularly severe symptoms or infections caused by less common types of fungi, remain insufficient.

Research on Recurring Vaginal Yeast Infections (RVVC)

The issue of recurrent infections—conditions involving periods of heightened symptoms—was studied for clotrimazol through trials that examine maintenance or prophylactic (preventive) regimens. These studies used in research exploring how symptoms change over time often compare the intermittent use of the medicine over a longer duration against other forms of prevention. The studies monitored recurrence endpoints, which tracked the frequency with which symptoms returned after the initial study period.

Research highlights that some maintenance regimens were associated with different patterns in the recurrence rate observed in the studies during the study period. The available evidence for recurring infections is limited, as fewer RCTs are dedicated exclusively to comparing different topical maintenance schedules. The evidence quality varies across studies, and data for extended periods beyond six months to one year are still emerging. The data show patterns related to short-term prevention, but the long-term effects are not fully established.

Evidence for Fungal Skin Conditions (Dermatophytosis)

The topical cream and solution formulations of the medicine was evaluated in dermatophytosis, which are common fungal skin conditions marked by functional limitations such as itching and scaling. Research examined the use in adults and children, typically with conditions associated with acute or disruptive episodes like athlete's foot. The trials monitored outcomes related to physical discomfort and mycological outcomes, which assessed whether the fungal organism was successfully cleared from the skin.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Canifug (FAQ)

Q: Can I use Canifug with oral contraceptives (birth control pills)?

A: Official product information notes that clotrimazole vaginal products can reduce the effectiveness of latex contraceptives, such as condoms and diaphragms, due to potential material damage. Regulatory labels do not typically indicate a direct drug-drug interaction with oral hormonal contraceptives (birth control pills). However, patients are encouraged to consult with a healthcare professional regarding any specific concerns about their overall medication regimen.

Q: What are the common side effects of the suppository?

A: According to official safety documents, side effects are most often localized reactions at the application site. Common symptoms include a burning sensation, stinging, itching (pruritus), and redness (erythema) in or around the vagina. While the exact frequency is often hard to estimate from reports, local irritation may be considered common.

Q: Is it safe to use Canifug while pregnant or breastfeeding?

A: Regulatory documents state that use of vaginal products requires medical consultation if a patient is pregnant or breastfeeding. Although systemic absorption is minimal, special caution is advised during the first trimester of pregnancy. Official guidance advises caution if a patient is breastfeeding, and regulatory information advises against application to the breast area.

Q: Do the suppositories interact with any other medications I might be taking?

A: Official information highlights that the active ingredient may interact with certain orally administered immunosuppressants, specifically Tacrolimus and Sirolimus, potentially raising the concentration of these drugs in the blood. Since only a minimal amount of the medicine is absorbed from the vagina, interactions with most other systemic medications are generally considered unlikely. It is important for patients to disclose all medicines to their healthcare provider.

Q: How long does it take for Canifug to start working or for symptoms to improve?

A: Regulatory guidance often advises patients to seek medical consultation if their symptoms have not been relieved within one week after beginning treatment. It is generally advised that the medicine be used for the full prescribed duration, even if symptoms begin to improve quickly.

Q: What should I do if my symptoms don't improve after the 3-day treatment?

A: Official patient information states that if symptoms do not improve after completing the full treatment course, patients are advised to consult a physician. Medical consultation is also advised if symptoms return within two months or if the infection is frequently recurring.

Q: What are the signs of a severe allergic reaction to look out for?

A: Although rare, official safety profiles list severe allergic reactions (hypersensitivity/anaphylaxis). Signs may include fainting (syncope), low blood pressure (hypotension), difficulty breathing (dyspnea), or swelling of the face, lips, tongue, or throat. Immediate medical attention is necessary if these signs occur.

How should Canifug be stored and disposed of?

Official Storage and Disposal Instructions

Regulatory agencies establish strict conditions for storing and disposing of Canifug (clotrimazole products) to maintain product stability and safety. These requirements are derived from the official labeling and prescribing information.

Storage/Disposal Component	Official Regulatory Requirement
Temperature	Do not store above 30 C (or 25 C) and do not freeze.
Protection	Keep in the original container to protect from light and moisture.
Child Safety	Keep out of the sight and reach of children.
Handling	Keep the container tightly closed (where applicable).
Disposal	Dispose of all unused product and waste material, including the applicator, in accordance with local regulatory requirements. Do not flush the applicator down the toilet.